文献速递糖尿病肥胖与代谢综合征性腺与生殖内分泌

妊娠期二甲双胍治疗对多囊卵巢综合征女性未来代谢特征的影响

Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

本研究为一项随机对照试验的随访研究,纳入239名多囊卵巢综合征(PCOS)女性,比较妊娠期使用二甲双胍(2000 mg/日)或安慰剂对后续代谢健康的影响。平均随访7.7年(范围5-11年),131人(55%)参与随访。结果显示,二甲双胍组与安慰剂组在体重增加、BMI、腰臀比、血压、体成分、血脂、血糖、胰岛素水平及代谢综合征患病率方面均无差异。结论认为妊娠期二甲双胍治疗未影响PCOS女性7.7年随访时的代谢特征。

要点

  • 妊娠期二甲双胍治疗未改变PCOS女性7.7年随访时的体重增加(二甲双胍组2.1±10.5 kg vs 安慰剂组1.8±11.2 kg,P=0.834)。
  • 两组在BMI、腰臀比、血压、体成分、血脂、血糖、胰岛素及代谢综合征患病率上均无差异。
  • 本随访研究未对参与者进行干预,仅评估妊娠期二甲双胍暴露的远期代谢影响。

核心结论

  • 妊娠期二甲双胍治疗未影响PCOS女性7.7年随访时的代谢特征。

研究设计与样本

  • 一项随机对照试验的随访研究,原试验比较妊娠期二甲双胍与安慰剂对PCOS女性的影响。
  • 随访平均7.7年(范围5-11年),在三个大学医院、七个当地医院和一个妇科专科诊所进行。
  • 参与者为符合鹿特丹标准的多囊卵巢综合征女性,均为原Metformin in Pregnant PCOS Women研究的既往参与者。
  • 原研究干预为从妊娠早期至分娩每日服用二甲双胍2000 mg或安慰剂,本随访研究无干预。
  • 共邀请239名女性,131名(55%)参与随访。

主要发现

  • 随访期间体重增加在二甲双胍组为2.1 ± 10.5 kg,安慰剂组为1.8 ± 11.2 kg,组间无显著差异(P = 0.834)。
  • 随访时两组在BMI、腰臀比、血压、体成分、血脂、血糖和胰岛素水平方面均无差异。
  • 随访时两组代谢综合征患病率无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS). Metformin may also benefit future health by modulating increased metabolic stress during pregnancy. OBJECTIVE: To investigate whether metformin during pregnancy modified future metabolic health in women with PCOS. DESIGN: Follow-up study of a randomized controlled trial that compared metformin with placebo in women with PCOS. Mean follow-up period was 7.7 years (range, 5 to 11 years). SETTING: Three university hospitals, seven local hospitals, and one gynecological specialist practice. PARTICIPANTS: Women with PCOS according to Rotterdam criteria; all former participants in the Metformin in Pregnant PCOS Women Study. INTERVENTION: Metformin 2000 mg daily or placebo from first trimester to delivery in the original study. No intervention in the present follow-up study. MAIN OUTCOMES AND MEASURES: Main outcome measure was weight gain in the follow-up period. Weight, body mass index (BMI), waist and hip circumferences, and blood pressure (BP) were registered. Body composition was assessed by bioelectrical impedance analysis, and fasting lipids, glucose, and insulin were analyzed. RESULTS: Of 239 invited women, 131 (55%) participated in the follow-up. Weight gain was similar in women given metformin (2.1 ± 10.5 kg) and women given placebo (1.8 ± 11.2 kg) at 7.7 years' follow-up after pregnancy (P = 0.834). No difference was found in BMI, waist/hip ratio, BP, body composition, lipids, glucose and insulin levels, or prevalence of metabolic syndrome at follow-up between those treated with metformin and those treated with placebo during pregnancy. CONCLUSION: Metformin treatment during pregnancy did not influence the metabolic profile in women with PCOS at 7.7 years of follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Underdal MO, Stridsklev S, Oppen IH, et al. Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? J Clin Endocrinol Metab. 2018. PMID: 29659896. doi:10.1210/jc.2018-00485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。